Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

PPARG - peroxisome proliferator-activated receptor...

Canis lupus familiaris

Nemoto, S. et al., Kabir, M. et al., Uchino, H. et al., Leray, V. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PPARG

PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation [1].

High impact information on PPARG

Northern blot analysis revealed an increase in the ratio of visceral to subcutaneous (v/s ratio) mRNA expression of both lipoprotein lipase (LPL) and peroxisome proliferator-activated receptor-gamma (PPARgamma) [2].
We conclude that 1) chronic MR leads to intramyocyte myocardial lipid accumulation and contractile dysfunction, and 2) administration of the PPAR-gamma agonist rosiglitazone ameliorates MR-induced LV dysfunction accompanied by a decline in lipid content [1].
Modulation of uncoupling protein 1 and peroxisome proliferator-activated receptor gamma expression in adipose tissue in obese insulin-resistant dogs [3].
FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs [4].

References

PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Nemoto, S., Razeghi, P., Ishiyama, M., De Freitas, G., Taegtmeyer, H., Carabello, B.A. Am. J. Physiol. Heart Circ. Physiol. (2005) [Pubmed]
Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Kabir, M., Catalano, K.J., Ananthnarayan, S., Kim, S.P., Van Citters, G.W., Dea, M.K., Bergman, R.N. Am. J. Physiol. Endocrinol. Metab. (2005) [Pubmed]
Modulation of uncoupling protein 1 and peroxisome proliferator-activated receptor gamma expression in adipose tissue in obese insulin-resistant dogs. Leray, V., Gayet, C., Martin, L., Dumon, H., Siliart, B., Nguyen, P. J. Nutr. (2004) [Pubmed]
FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Uchino, H., Kim, T., Lam, T.K., Yoshii, H., Klement, P., Williams, W., Kawamori, R., Giacca, A. Metab. Clin. Exp. (2005) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg